aminoimidazole carboxamide has been researched along with decitabine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liang, HT; Liu, W; Tang, L; You, Y; Zhu, XJ; Zhu, XY; Zou, P | 1 |
| Li, X; Liang, L; Liu, J; Nie, L; Peng, YL; Wang, XL; Zhang, J | 1 |
2 other study(ies) available for aminoimidazole carboxamide and decitabine
| Article | Year |
|---|---|
AICAR and Decitabine Enhance the Sensitivity of K562 Cells to Imatinib by Promoting Mitochondrial Activity.
Topics: Aminoimidazole Carboxamide; Apoptosis; Cell Line, Tumor; Cell Proliferation; Decitabine; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mitochondria; Protein Kinase Inhibitors; Ribonucleotides | 2020 |
AICAR suppresses cell proliferation and synergizes with decitabine in myelodysplastic syndrome via DNA damage induction.
Topics: Adenylate Kinase; Aminoimidazole Carboxamide; AMP-Activated Protein Kinase Kinases; Animals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Decitabine; DNA Damage; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Mice; Myelodysplastic Syndromes; Ribonucleotides; Xenograft Model Antitumor Assays | 2021 |